The base editing market is projected to reach USD 549 million by 2028 from an estimated USD 270 million in 2023, at a CAGR of 15.2% during the forecast period. Factors like the rising prevalence of genetic diseases, coupled with advancements in molecular biology and biotechnology, has spurred research and development efforts in base editing technologies. Additionally, the growing investment in gene therapy and the biopharmaceutical sector further accelerates the expansion of the base editing market.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371

Based on product & service, the base editing market is segmented into products and services. The product segment is further categorized as platform, kits & reagents, plasmids, and base editing libraries. The service segment is further categorized as gRNA design/synthesis, cell line engineering, and other services. Platform accounted for the largest share of the global base editing market in 2022. The large share of this segment can primarily be attributed to the increasing demand for base editing in molecular studies and the discovery of new therapies.

Based on type, the global base editing market is segmented into DNA base editing, and RNA base editing. In 2022, DNA-targeted base editing accounted for the largest share of the base editing market. The large share of this segment can be attributed to the factor that DNA base editing leads to changes in the genomic DNA sequence, making the edits permanent. This can be advantageous when long-lasting or heritable modifications are desired, as the edited DNA is passed on to subsequent generations of cells.

Based on targeted base, the base editing market has been segmented into cytosine base editing, and adenine base editing. In 2022, cytosine base editing accounted for the largest market share because cytosine base editors (CBEs) are designed to convert a C-G base pair to a T-A base pair. This type of transition is more common in naturally occurring DNA sequences, making cytosine editing suitable for introducing changes that are biologically relevant.

Based on application, the base editing market has been segmented into drug discovery & development, agriculture, and veterinary. In 2022, the drug discovery & development segment accounted for the largest share of the base editing market. The large share of this segment can be attributed to the potential of base editing for developing novel therapeutic interventions by correcting disease-causing mutations at the DNA or RNA level. This is especially relevant for genetic disorders where a single nucleotide mutation is responsible for the disease.

Based on end users, the base editing market has been segmented into pharmaceutical & biotechnology companies, academic research institutes, and contract research organizations. In 2022, the pharmaceutical & biotechnology segment accounted for the largest share of the base editing market. The large share of this segment is due to the potential of base editing in drug development; companies in the pharmaceutical and biotechnology sectors are investing in this technology to secure intellectual property, technology, and product rights and gain a competitive advantage in the rapidly evolving field of genome editing. For instance, in October 2023, Beam Therapeutics announced an agreement with Eli Lilly and Company (Lilly) to acquire certain rights under Beam’s collaboration and license agreement with Verve Therapeutics, Inc., including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease.

The key regional markets for the global base editing market are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market. The large share of this region is due to the robust biotechnology and pharmaceutical industry, with numerous companies dedicated to drug discovery, development, and therapeutic applications. These companies actively invest in and adopt emerging technologies like base editing for advancing their research and product pipelines. However, most of the growth in the market is expected from emerging countries across Asia Pacific. During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market. Factors such as the emergence of CROs for outsourcing drug discovery-related research projects and increasing pharmaceutical drug pipelines are driving growth in these markets.

Key players in the global Base editing market include Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), EdiGene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI-Biodesign (China), KromaTiD, Inc. (US), and GenKOre. (South Korea).

The global base editing market is experiencing remarkable growth, fueled by the rising prevalence of genetic diseases and the urgent need for precise gene editing technologies. Valued at $270 million in 2023, this market is projected to reach $549 million by 2028, expanding at an impressive compound annual growth rate (CAGR) of 15.2%.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371

Driving this growth is the increasing recognition of the role genetic mutations play in various diseases. As rare and orphan diseases become more prevalent, the demand for innovative therapies has skyrocketed, propelling base editing to the forefront of rare disease research and treatment.

Base editing, a cutting-edge technology, offers a more precise alternative to traditional CRISPR-Cas9 methods, potentially minimizing off-target effects. However, ethical and safety concerns remain a significant barrier to its widespread adoption. The inadvertent modifications to DNA can have detrimental consequences, necessitating a vigilant focus on enhancing the safety and specificity of these techniques.

Nonetheless, the expanding pipeline of gene therapy products and regulatory approvals present significant opportunities for the base editing market. With over 1,000 gene therapy products in development, including over 200 in clinical trials, the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases is promising.

One of the primary challenges facing the industry is the issue of off-target effects – unintentional modifications to DNA sequences other than the intended target. Researchers are continually working to improve the design and engineering of base editors to reduce this risk and enhance precision.

The base editing market ecosystem comprises a diverse array of stakeholders, including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, reagent and kit suppliers, technology providers, data management and analysis providers, regulatory authorities, and collaborative networks. Their interactions and collaborations drive the advancement of base editing products and services, enhance drug discovery processes, and develop new therapeutics.

Geographically, North America currently dominates the base editing market, thanks to its well-established infrastructure for funding research and development initiatives and a supportive regulatory environment for life sciences innovation.

Key players in the global base editing market include Danaher Corporation, Merck KGaA, Revvity, Maravai LifeSciences, GenScript, Beam Therapeutics, Intellia Therapeutics, Inc., Cellectis, ElevateBio, Creative Biogene, Bio Palette Co., Ltd, Addgene, Synthego, EdiGene, Inc., Shape TX, Pairwise, ProQR Therapeutics, QI-Biodesign, KromaTiD, Inc., and GenKOre.

As the base editing market continues to grow, it holds the potential to revolutionize the treatment of genetic disorders and usher in a new era of personalized medicine, where precision and efficacy are at the forefront of therapeutic interventions.

Base Editing Market in terms of revenue was estimated to be worth $270 million in 2023 and is poised to reach $549 million by 2028, growing at a CAGR of 15.2% from 2023 to 2028 according to a new report by MarketsandMarkets™.

Growing interest in gene editing technologies, including base editing, has attracted substantial funding and investment from both public and private sources. This financial support is crucial for research and development efforts, accelerating the commercialization of base editing technologies. However, ethical & safety concerns are the factors restraining market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371

By product and service, the base editing market has been further categorized as products and services. The service segment is further categorized as gRNA design, cell line engineering, and other services. The product segment is further categorized as platform, kits & reagents, plasmids, and base editing libraries. Platform accounted for the largest share of the global base editing market in 2022. The large share of this segment can primarily be attributed to the factor that it offers integrated solutions that combine various elements required for the editing process, such as the base editor protein, guide RNA, and delivery mechanisms. This integration simplifies the workflow for researchers, as they can obtain a complete solution from a single source rather than assembling individual components.

Based on the type, the global base editing market is segmented into RNA base editing, and DNA base editing. In 2022, DNA base editing accounted for the largest share of the base editing market and the segment is expected to grow at a higher rate during the forecast period. The prominence of this segment is mainly attributed to the factor that once a base is edited in the DNA, the change is more stable over time compared to RNA-based editing. RNA is typically transient in cells, and the edits made to RNA may not persist as long as those made to DNA.

Based on end users, the base editing market has been segmented into pharmaceutical & biotechnology companies, academic research institutes, and contract research organizations. In 2022, the pharmaceutical & biotechnology segment accounted for the largest share of the base editing market. One of the major factors driving the growth of this segment is that base editing enables precise modifications at the DNA or RNA level, allowing pharmaceutical and biotech companies to develop targeted therapies for specific genetic diseases. This aligns with the industry’s shift toward precision medicine, where treatments are tailored to the individual genetic makeup of patients.

The base editing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The availability of funding, both public and private, plays a crucial role in the development and commercialization of advanced technologies. North America has a well-established infrastructure for funding research and development initiatives, providing financial support to companies working on base editing technologies.

Key Market Players of Base Editing Industry:

Key players in the base editing market include Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), Edigene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI- Biodesign (China), KromaTiD, Inc. (US), and GenKOre. (South Korea).

Base Editing Market Recent Developments:

• In May 2023, Revvity entered into a license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.
• In July 2022, Beam Therapeutics entered a collaboration with Verve Therapeutics. Beam Tx granted Verve Tx a license toward an additional liver-mediated cardiovascular disease target.
• In February 2022, Intellia Therapeutics acquired Rewrite Therapeutics; a private biotechnology company focused on advancing novel DNA writing technologies. This acquisition has expanded Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologies.